NICE recommends Ezetrol (ezetimibe) in primary (heterozygous-familial and non-familial) hypercholesterolaemia- Merck Inc
NICE has published draft guidance recommending Ezetrol (ezetimibe), from Merck, as an option for some adults with primary (heterozygous familial and non-familial) hypercholesterolaemia.
The draft guidance provisionally recommends ezetimibe on its own for adults with primary heterozygous-familial and non-familial hypercholesterolaemia when a statin is considered inappropriate or is not tolerated, only if they need lipid modification therapy for the primary prevention of cardiovascular disease and have both type 2 diabetes and a ≥20% 10-year risk of developing cardiovascular disease according to the QRISK2 risk assessment tool, or they need lipid-modification therapy for the secondary prevention of cardiovascular disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins